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Essential thrombocythemia is a rare myeloproliferative disorder in pediatrics. This myeloproliferative disorder 
is charactherized by thrombocytosis and hyperplasia of megakaryocytes in the bone marrow. Other cell lines 
are not involved. JAK2V617F mutation has been identified in approximately half the patients with this 
disorder. We describe a 12-year-old boy with essential throbocythemia. The patient had a persistent 
thrombocytosis over 600x109 /L and the time of diagnosis, his platelet count ranged between 900x109and 
2150x109/L. Megakaryocytes in the bone marrow were increased in number. The chromosomal analysis was 
normal and bcr/abl rearrangement was negative. He remained asymptomatic throughout the follow-up period. 
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INTRODUCTION 
   Essential thrombocythemia (primary 
thrombocytosis) is rare in children occurring in 
approximately 1/1000,000 children.1-6 ET is a 
myeloproliferative disorder characterized by 
thrombocytosis and hyperplasia of the 
megakaryocytes in the bone marrow.1, 2 Other cell 
lines are not involved.1 Reactive (secondary) 
thrombocytosis is a more common cause of this 
elevated platelet count among children and the 
common causes of this entity such as infections, 
iron deficiency anemia, surgery, cancer, major 
trauma and post spelenectomy need to be excluded 
prior to considering the diagnosis ET.1, 2, 3 ET is 
primarily a diagnosis of exclusion2, 6, 8, 9 and is 
considered in the presence of a persistent 
thrombocytosis of greater than 600x109/L in the 
absence of alternative cause.2 These patients may 
be predisposed to thrombosis or hemorrhage.3 
JAK2V617F mutation has been identified in 
approximately half the patients with this disorder.1, 
2, 4, 7, 9 It occurs in more than 90% of patients with 
polycythemia vera and primary myeloproliferative 
disease1, 2 and 30% of cases of ET.4, 7 Familial 
thrombocythemia, a rare condition,6 is similar to ET 
but differs from ET in that the platelet count  is 
usually significantly lower than ET associated with a 
lower incidence of hepatomegaly, and with fewer 
associated thrombotic complications.1, 2, 4, 5, 6 No 
familial case converted to leukemia or 
myelofibrosis.1, 2, 6 
 
CASE REPORT 
   We describe a 10 years old male with an 
incidental finding of an elevated platelet count. This 
patient had been admitted due to upper respiratory 
tract infection. His post medical history was 
unremarkable with a normal birth history and was 
taking no medications. Immunizations status was up 
to date. The platelet count at the time of referral 
was 950x109/L.  The physical examination was 
normal with the exception of mild splenomegaly 
(just palpable splenomegaly). He had lower leg pain 
but deep vein thrombosis ruled out with color 
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dupler ultrasonography.  His parent platelet count 
was normal and there was no family history of 
thrombocytosis. His white blood cell count and 
differential count were unremarkable, and platelet 
size was not enlarged. Hb, ESR and C-reactive 
protein were all within normal ranges. Bone 
marrow examination was normocellular with 
relatively normal numbers and maturation of 
erythroid and myeloid lineages but show clusters of 
large megakaryocytes with increased 
hyperlobulated nuclei (Fig-1). Myeloblasts are about 
5% of all nucleated cells. Bone marrow biopsy show 
remarkable bony trabeculae and marrow spaces 
contain hematopoietic elements with 
predominance of large hyperlobulated 
megakaryocytes. Reticulin staining was negative for 
myelofibrosis. The overall histological features 
suggest chronic myeloproliferative disorder without 
myelofibrosis suggestive of ET. Cytogentic showed 
normal 46, XY karyotype. No bcr/abl chimaeric 
transcript was demonstrated by reverse 
transcription polymerase chain reaction. JAK2-
V617F mutation was negative. Evaluation of the 
MPL W515L/K gene was negative in the patient. He 
received low dose aspirin (80mg/day). Her platelet 
count ranging from 303x109 to2131x109 /L. He was 
admitted to hospital because of anxiety and right 
lower leg pain. At this time his platelet count was 
2131x109/L and we started hydroxyurea 1000mg 
and anagrelide 2mg for him. The mean platelet 
count was 1029x109/L. The platelet count has 
shown a trend of gradual fall over the past year and 




Figure 1 Bone marrow aspiration showed megakaryocytic 
hyperplasia (magnification × 40) 
DISCUSSION 
   Throbocytosis is relatively common in young 
children occurring in 3% to 13% of children.5, 8 
Extreme thrombocytosis (platelet >1000,000) is 
uncommon, occurring in less than 2% of children.8 
Almost all reported case of throbocytosis in children 
are secondary to infection, iron deficiency, surgery, 
cancer, postsplenectomy, chronic inflammation, 
collagen vascular and renal disease, langerhans cell 
histocytosis, hemolytic anemia, Kawasaki disease 
drugs.1, 2, 3, 4, 8 Essential thrombocythemia extremely 
rare in childhood,1-8 with an estimated incidence of 
0.09 case per million for children younger than 14 
years 60 times lower than in adults.4 Based on the 
criteria of the PVSG approximately 75 children have 
been reported with essential thrombocythemia 
between 1966 and 2000.2 Edwin B.Robins desceibed 
a 2 years old male with an incidental finding of an 
elevated platelet count discovered on health 
maintenance screening. The platelet count at the 
time of referral was 900x109/L, and his physical 
examination was remarkable for bony abnormalities 
of the right upper extremity and hand.4 Maria Luigia 
Randi et al., reported five children with essential 
thrombocythemia. Moreover only one case of them 
was infant.5 Abeer Abd EI-Moneim et al., also 
reported 12 cases of children with essential 
thrombocythemia.9 Dror et al., from the Hospital for 
sick children in Toronto reviewed the clinical course 
of 36 children with ET. Forty eight children with ET 
were described in the medical literature prior to 
2006, with the age ranging from 6 weeks to 18 
years.6 ET in children is not always a benign entity, 
in adults with ET, thrombosis is the most common 
and hazardous complication, occurring in about 
40% of patients. In contrast, most children with ET 
seen to have few major thrombotic complication.5 
Out of the 42 children with ET revied by Dror Four 
children experienced severe bleeding episods, six 
children had mild hemorrhage, four children 
suffered from severe arterial thrombosis, and in 
two cases venous thrombosis were documented. 
Two children had headache, erythromelalgia and 
limb paresthesia. Splenomegaly was found in 44%, 
hepatomegaly in 22% of the patients.6 Children with 
thrombocytosis may develop unspecific symptoms 
that are potentially related to thrombocytosis. The 
clinical course is heterogeneous.8, 9 Some patients 
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may recover spontaneously.9 Due to the lower 
incidence of ET in children optimal first line therapy 
remains unclear in this age group.6 Furthermore 
treatment of asymptomatic patients remains 
problematic. Hydrxoyurea has been used 
successfully in patients with ET.4, 6, 9, 10 Anagrelide 
has a high specificity toward megakaryocytes and 
effectively controls extreme thrombocytosis in 
adults and children.1, 2, 3, 4, 6 The use of anagrelide to 
treat children with ET has been described since 
1991 and long term use of anagrelide has been 
studied in adults with a 93% response rate in a 
prospective cohort of 335 adults, and in children.4 
Indication for treatment included thrombotic 
events, major bleeding, minor bleeding, or merely 
high platelet counts.6 Antiplatelet agents such as 
low-dose acetylsalicylic acid or dipyridamol have 
proved efficacious in preventing recurrence of 
thrombosis in the acral, coronary and cerebral 
arterial circulations in patients with ET, and have 
been recommended as initial therapy in patients 
with minor benign problems.6 
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